Is the use of RAS inhibitors safe in the current era of COVID-19 pandemic?

Is the use of RAS inhibitors safe in the current era of COVID-19 pandemic?

Jin Ho Shin, Dae-Hee Kim, Hyeon Chang Kim, Ju Han Kim, Sungha Park, Eun Joo Cho, Hae-Young Lee, Kwang-Il Kim, Wook-Jin Chung, Sang Hyun Ihm, Il Suk Sohn, Wook Bum Pyun, Ki-Chul Sung, Sung Kee Ryu, on behalf of the Korean Society of Hypertension

Abstract Antihypertensive drugs are one of the most widely used pharmacologic agent in the world and it is predominantly used in the elderly subjects. Pneumonia is the most common cause of death in the extremely old subject. During infection and its complication such as sepsis, hypotension could be exacerbated by antihypertensive drugs because homeostasis mechanisms such as sodium balance, renin angiotensin aldosterone system and/or sympathetic nervous system can be mitigated by antihypertensive drug therapy. Severe Acute Respiratory Syndrome-Coronavirus-1 and 2 viral surface protein is known to attach angiotensin converting enzyme 2 (ACE2) on the cell membrane to facilitate viral entry into the cytoplasm. Despite the theoretical concerns of increased ACE2 expression by Renin-Angiotensin-Aldosterone system (RAS) blockade, there is no evidence that RAS inhibitors are harmful during COVID-19 infection and have in fact been shown to be beneficial in animal studies. Therefore, it is recommended to maintain RAS blockade during the current corona virus pandemic.

2020

infection, hypertension, SARS, SARS-CoV-2, COVID-19, 2019 novel coronavirus

DOI: 10.1186/s40885-020-00144-0

Clinical Hypertension

BMC

Internal medicine, Medicine